Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging
Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging
复制标题
DOI：
10.1007/s00261-018-1615-z
复制
发表时间：
2018-04
影响因子：
2.4
通讯作者：
S. Murata;S. Matsushima;Yozo Sato;H. Yamaura;Mina Kato;T. Hasegawa;K. Muro;Y. Inaba
中科院分区：
文献类型：
--
作者：
S. Murata;S. Matsushima;Yozo Sato;H. Yamaura;Mina Kato;T. Hasegawa;K. Muro;Y. Inaba
目的本研究的目的是预测治疗反应的结直肠癌肝转移（CLM）使用相对肿瘤增强（RTE）的肝胆阶段（HBP）的患者没有history.Materials和方法在这项回顾性研究中，我们招募了26例患者[14男，12女;中位数年龄：58岁（范围37-82岁）]，2011年12月至2017年5月期间患有CLM，无化疗史。在开始化疗和HBP的RTE之前进行甘氨乙酸增强磁共振成像。反应进行了评价，使用RECIST版本。1.1，和无进展生存期（PFS）estimated.ResultsBased的RECIST版本。1.1，有15个应答者和11个无应答者。在肿瘤中，应答者组的平均治疗前RTE值显著高于无应答者组（分别为37.2% ± 10.9% vs. 17.9% ± 10.5%;P= 0.0006）。当检测应答者的参数阈值包括RTE值24.2%（曲线下面积值0.90）时，敏感性和特异性分别为93.3%和72.7%。26例患者的中位随访期为602天（范围160-1971天）。虽然没有显着差异，观察各组之间的PFS，高RTE组往往需要更长的时间比低RTE组（PFS的高RTE组没有达到中位数）。
PurposeThis study aimed to predict the treatment response for colorectal liver metastases (CLM) using relative tumor enhancement (RTE) of the hepatobiliary phase (HBP) for patients with no history of chemotherapy.Materials and methodsIn this retrospective study, we enrolled 26 patients [14 males, 12 females; median age: 58 years (range 37–82 years)] with CLM and no history of chemotherapy between December 2011 and May 2017. Gadoxetic acid-enhanced magnetic resonance imaging was performed before starting chemotherapy and RTE of HBP. The response was evaluated using RECIST ver.1.1, and progression-free survival (PFS) was estimated.ResultsBased on the RECIST ver.1.1, there were 15 responders and 11 non-responders. In the tumor, the mean pretreatment RTE values were significantly higher in the responders group than in the non-responders group (37.2% ± 10.9% vs. 17.9% ± 10.5%, respectively;P= 0.0006). When the threshold values of parameters for detecting responders comprised the RTE value of 24.2% (area under the curve value, 0.90), the sensitivity and specificity were 93.3% and 72.7%, respectively. The median follow-up period for 26 patients was 602 days (range 160–1971 days). Although no significant differences were observed in PFS between the groups, the high RTE group tended to take longer to progress than the low RTE group (PFS of the high RTE group did not reach the median).ConclusionThis study suggests that the RTE value of CLM could be a potential biomarker to predict early treatment response.